1. Core Product Specifications

Product Name: Icotrokinra
Research Code: JNJ-77242113, JNJ-2113, PN-235
CAS No.: 2763602-16-8
Molecular Formula: C??H???N??O??S?
Molecular Weight: 1898.17 Da
Appearance: White to off-white lyophilized powder, loose texture, non-caking, free of visible impurities
Purity: ≥99.8% (HPLC tested, drug research grade)
Core Activity: Highly selective IL-23 receptor antagonist, potent inhibitor of STAT3 phosphorylation
IC50 Activity: IC50 = 5.6 pM for inhibiting IL-23-induced STAT3 phosphorylation; IC50 = 18.4 pM for suppressing IFN-γ production in NK cells
Moisture Content: ≤2.0%
Heavy Metals: ≤10ppm
Endotoxin: ≤0.1EU/mg
Residue on Ignition: ≤0.1%
Solubility: Freely soluble in pure water, DMSO and aqueous buffer systems, forming clear and stable solutions
Transport Condition: Room temperature transportation with light protection
Storage Condition: Long-term storage of dry powder at -20℃ in sealed, dry and dark environment; aliquot and store solutions at -20℃, strictly avoid repeated freeze-thaw cycles
Production Technology: Site-specific amino acid modification, solid-phase peptide synthesis, precise cyclization modification, multi-stage preparative HPLC purification, low-temperature vacuum freeze-drying technology
Product Attribute: Orally active targeted peptide, specific IL-23R antagonist, high-end raw material for anti-inflammatory innovative drug research
Shelf Life: 24 months for dry powder under standard sealed storage at -20℃
Usage Restriction: For scientific research and drug development only, not approved for general human clinical application

2. Professional Product Introduction

Icotrokinra (CAS: 2763602-16-8) is a new-generation orally available highly selective IL-23 receptor antagonist peptide developed by Janssen. It serves as a benchmark targeted compound for psoriasis and autoimmune inflammation research. Unlike ordinary laboratory short peptides, it possesses complete drug-grade developability and excellent oral bioavailability. This product accurately targets and binds to the IL-23 receptor, competitively blocking the activation of the downstream IL-23-mediated STAT3 signaling pathway. It exhibits ultra-high antagonistic activity with picomolar-level IC50 values, efficiently inhibiting the release of pro-inflammatory mediators such as IFN-γ and blocking the cascade of autoimmune inflammatory responses at the source. Compared with traditional injectable anti-inflammatory biologics, Icotrokinra features distinct advantages of oral administration, metabolic stability and target specificity without broad-spectrum immunosuppressive side effects. Currently under review for psoriasis indication, it is widely applied in autoimmune inflammation mechanism research, anti-inflammatory drug screening, IL-23/STAT3 pathway verification and inflammatory animal model establishment for high-end pharmaceutical R&D.